{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:37:33Z","timestamp":1777491453123,"version":"3.51.4"},"reference-count":44,"publisher":"FapUNIFESP (SciELO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trends Psychiatry Psychother."],"abstract":"<jats:p>Abstract  Introduction  There is an unpredictable pattern in the prescription of antipsychotics and other psychotropic medications for the treatment of schizophrenia, particularly in resource-limited settings in developing countries.  Objective  To determine the psychotropic prescriptions given to patients with schizophrenia in an outpatient clinic of a tertiary hospital and to describe the choices and trends of these prescriptions.  Methods  This was a cross-sectional descriptive study of prescriptions for adults with schizophrenia. After clinical consultation, patients\u2019 case notes were randomly selected over a period of 2 years. Using a structured form, data were extracted from the case notes including biodemographic data, psychotropic medications prescribed and changes made to these prescriptions. Data were analyzed by means of descriptive statistics.  Results  A total of 103 patients were selected, with a mean age of 35.96\u00b19.78 years; 48.5% were males and 51.5% were females; 33% were unemployed and 38% had been hospitalized in the past. There were 231 initial prescriptions and 228 current prescriptions, with about 2.2 prescriptions per patient. Haloperidol (mean dose 14.77\u00b16.28mg and 11.44\u00b15.55mg for initial and current) and other old-generation antipsychotics were the most commonly prescribed for new cases (98%). Mean duration of psychotropic use was 7.78\u00b15.6 years. All the patients were prescribed trihexyphenidyl, and 56.3% of the patients had their medications changed as a result of side effects.  Conclusion  There was a very high preference for the use of first-generation antipsychotics for all treatment settings (in- and outpatients), a pattern that is likely to persist.<\/jats:p>","DOI":"10.1590\/2237-6089-2016-0088","type":"journal-article","created":{"date-parts":[[2017,8,31]],"date-time":"2017-08-31T13:38:19Z","timestamp":1504186699000},"page":"165-172","source":"Crossref","is-referenced-by-count":3,"title":["Psychotropic prescriptions for the treatment of schizophrenia in an outpatient clinic"],"prefix":"10.1590","volume":"39","author":[{"given":"Christopher Izehinosen","family":"Okpataku","sequence":"first","affiliation":[{"name":"Bingham University,  Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Tawani","sequence":"additional","affiliation":[{"name":"Ahmadu Bello University Teaching Hospital,  Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","published-online":{"date-parts":[[2017,8,31]]},"reference":[{"key":"ref1","series-title":"The global burden of disease","author":"Murray CJL","year":"1996"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4088\/JCP.10075su1.01","article-title":"Antipsychotics in the treatment of schizophrenia: an overview","volume":"72","author":"Tandon R","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"ref3","series-title":"Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment","author":"Stroup TS"},{"key":"ref4","first-page":"497","article-title":"The treatment of psychosis by a method derived neurolytic the hibernotherapie: the 4560 RP used only in prolonged treatment continuation","volume":"50","author":"Delay J","year":"1952","journal-title":"Med Alien Neurol"},{"key":"ref5","first-page":"206","article-title":"A new vegetative stabilizer (the 4560 RP)","volume":"60","author":"Laborit H","year":"1952","journal-title":"Presse Med"},{"key":"ref6","first-page":"68","article-title":"Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis","volume":"57","author":"Lieberman JA","year":"1996","journal-title":"J Clin Psychiatry"},{"key":"ref7","article-title":"Prescribing of antipsychotics in UK primary care: a cohort study","volume":"4","author":"Marston L","year":"2012","journal-title":"BMJ Open"},{"key":"ref8","article-title":"Sociodemographic profile of utilization pattern of antipsychotic drugs among schizophrenic inpatients: a cross sectional study from western region of Nepal","volume":"13","author":"Banergee I","year":"2013","journal-title":"BMC Psychiatry"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.5455\/2320-6012.ijrms20140874","article-title":"Pharmacoepidemiological survey of schizophrenia in Central India","volume":"2","author":"Rode SB","year":"2014","journal-title":"Int J Res Med Sci"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"719","DOI":"10.3346\/jkms.2014.29.5.719","article-title":"Pattern of antipsychotic prescription to patients with schizophrenia in Korea: results from the health insurance review & assessment service-national patient sample","volume":"29","author":"Park SC","year":"2014","journal-title":"J Korean Med Sci"},{"key":"ref11","first-page":"1","article-title":"Drug Prescription Patterns in Schizophrenia Outpatients: Analysis of Data from a German Health Insurance Fund","volume":"41","author":"Weinbrenner S","year":"2008","journal-title":"Pharmacopsychiatry"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"122","DOI":"10.9758\/cpn.2011.9.3.122","article-title":"Factors that influence the prescription of antipsychotics for patients with schizophrenia in China","volume":"9","author":"Si TM","year":"2011","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1600-0447.1983.tb06984.x","article-title":"Psychotropic drug prescription in Nigeria","volume":"68","author":"Famuyiwa OO","year":"1983","journal-title":"Acta Psychiatr Scand"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/2045125316672134","article-title":"Prevalence and correlates of antipsychotic polypharmacy among outpatients with schizophrenia attending a tertiary psychiatric facility in Nigeria","volume":"7","author":"Igbinomwanhia NG","year":"2017","journal-title":"Ther Adv Psychopharmacol"},{"key":"ref15","first-page":"332","article-title":"Prescription Pattern of Antipsychotic Drugs-A Case study of a Neuro-psychiatric Hospital in North-Western Nigeria","volume":"95","author":"Kabir A","year":"2013","journal-title":"Eur J Sci Res"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4103\/2141-9248.109499","article-title":"Prevalence and correlates of \u201cHigh dose\u201d antipsychotic prescribing: findings from a hospital audit","volume":"3","author":"Adesola AO","year":"2013","journal-title":"Ann Med Health Sci Res"},{"key":"ref17","first-page":"261","article-title":"Prescribing habits for psychiatric in-patients admissions in a Nigerian psychiatric hospital","volume":"24","author":"Adamson TA","year":"1995","journal-title":"Afr J Med Sci"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/00004714-199708000-00010","article-title":"Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol","volume":"17","author":"Chouniard G","year":"1997","journal-title":"J Clin Psychopharmacol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2165\/00023210-200418130-00004","article-title":"Impact of atypical antipsychotics in quality of life in patients with schizophrenia","volume":"18","author":"Award AG","year":"2004","journal-title":"CNS Drugs"},{"key":"ref20","doi-asserted-by":"crossref","DOI":"10.1016\/S0924-977X(15)30733-1","article-title":"Patterns of antipsychotics prescription in a Psychiatric ward in Lisbon. A cross-sectional study","volume":"25","author":"Duarte M","year":"2015","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1001\/archpsyc.60.6.565","article-title":"Sex differences in the risk of schizophrenia: evidence from meta-analysis","volume":"60","author":"Aleman A","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1034\/j.1600-0447.2002.1169.x","article-title":"Quality of life in patients with schizophrenia in five European countries: the EPSILON study","volume":"105","author":"Gaite L","year":"2002","journal-title":"Acta Psychiatr Scand"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1192\/bjp.bp.105.020982","article-title":"Rates and correlates of employment in people with schizophrenia in the UK, France and Germany","volume":"191","author":"Marwaha S","year":"2007","journal-title":"Br J Psychiatry"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.schres.2009.06.008","article-title":"Factors influencing the choice of new generation antipsychotic medication in the treatment of patients with schizophrenia","volume":"113","author":"Edlinger M","year":"2009","journal-title":"Schizophr Res"},{"key":"ref25","doi-asserted-by":"crossref","DOI":"10.1186\/1471-244X-12-27","article-title":"Choice of antipsychotic treatment by European psychiatry trainees: are decisions based on evidence?","volume":"12","author":"Jauhar S","year":"2012","journal-title":"BMC Psychiatry"},{"key":"ref26","series-title":"Comprehensive textbook of psychiatry","first-page":"1591","volume-title":"Antipsychotic drugs","volume":"5","author":"Davis JM","year":"1989"},{"key":"ref27","series-title":"Schizophrenia: treatment of acute psychotic episodes","first-page":"61","volume-title":"Pharmacologic treatment","author":"Baldessarini RJ","year":"1990"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/schbul\/21.4.567","article-title":"Conventional antipsychotic medications for schizophrenia","volume":"21","author":"Dixon LB","year":"1995","journal-title":"Schizophr Bull"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/schbul\/13.1.133","article-title":"Treatment of schizophrenia","volume":"13","author":"Kane JM","year":"1987","journal-title":"Schizophr Bull"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1600-0447.2009.01425.x","article-title":"Anti-psychotic prescribing trends: a review of pharmaco epidemiological studies","volume":"121","author":"Verdoux H","year":"2010","journal-title":"Acta Psychiat Scand"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman JA","year":"2005","journal-title":"N Engl J Med"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.63.10.1079","article-title":"Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)","volume":"63","author":"Jones PB","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta10170","article-title":"Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment","volume":"10","author":"Lewis SW","year":"2006","journal-title":"Health Technol Assess"},{"key":"ref34","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.321.7273.1371","article-title":"Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis","volume":"321","author":"Geddes J","year":"2000","journal-title":"BMJ"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1370\/afm.749","article-title":"Influence of patients\u2019 socioeconomic status on clinical management decisions: a qualitative study","volume":"6","author":"Bernheim SM","year":"2008","journal-title":"Ann Fam Med"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1600-0447.2008.01310.x","article-title":"Side effects of antipsychotics medication and health-related quality of life","volume":"119","author":"Bebbington PE","year":"2009","journal-title":"Acta Psychiat Scand"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/10401230209149099","article-title":"Extrapyramidal side effects of antipsychotics treatment: scope of problem and impact on outcome","volume":"14","author":"Tandon R","year":"2002","journal-title":"Ann Clin Psychiatry"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/oxfordjournals.schbul.a006926","article-title":"The mount Sanai conference on the pharmacology of Schizophrenia","volume":"28","author":"Marder SR","year":"2002","journal-title":"Schizophr Bull"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/archpsyc.1974.01760130049008","article-title":"Why do schizophrenic patients refuse to take their drugs?","volume":"31","author":"Van Putten T","year":"1994","journal-title":"Arch Gen Psychiatry"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1192\/bjp.bp.111.101485","article-title":"Extrapyramidal motor side-effects of first-and second-generation antipsychotics drugs","volume":"200","author":"Peluso MJ","year":"2012","journal-title":"Br J Psychiatry"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1176\/ps.2009.60.9.1175","article-title":"Off-label use of antipsychotic medications in the department of Veterans Affairs health care system","volume":"60","author":"Leslie DL","year":"2009","journal-title":"Psychiatr Serv"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00003495-200161010-00011","article-title":"Olanzapine: an updated review of its use in the management of schizophrenia","volume":"61","author":"Bhana N","year":"2001","journal-title":"Drugs"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.socscimed.2009.05.001","article-title":"The promotion of olanzapine in primary care: an examination of internal industry documents","volume":"27","author":"Spielmans GI","year":"2009","journal-title":"Soc Sci Med"},{"key":"ref44","article-title":"Practice guideline for the Treatment of patients with Schizophrenia, Second edition","volume":"161","author":"Lehman FA","year":"2004","journal-title":"Am J Psychiatry"}],"container-title":["Trends in Psychiatry and Psychotherapy"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/trends\/v39n3\/2238-0019-trends-2237-6089-2016-0088.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,5]],"date-time":"2018-03-05T21:11:29Z","timestamp":1520284289000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S2237-60892017000300165&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,31]]},"references-count":44,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,9]]}},"alternative-id":["S2237-60892017000300165"],"URL":"https:\/\/doi.org\/10.1590\/2237-6089-2016-0088","relation":{},"ISSN":["2238-0019","2237-6089"],"issn-type":[{"value":"2238-0019","type":"electronic"},{"value":"2237-6089","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8,31]]}}}